Related Experiment Video
Updated: May 31, 2026
10:27
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Two patients with extremely elevated tumor markers: where is the malignancy?
Patrick P J van der Veek1, Wouter H de Vos Tot Nederveen Cappel, Alexandra M J Langers
1Departments of Internal Medicine, Gastroenterology, and Hepatology, Medisch Centrum Haaglanden, P.O. Box 432, 2501 CK The Hague, The Netherlands.
Gastroenterology Research and Practice
|July 16, 2011
Summary
Elevated serum tumor markers can indicate benign conditions, not just cancer. These markers, like alpha-fetoprotein and CA19-9, can be falsely high in non-malignant diseases, challenging their diagnostic use.
Area of Science:
- Oncology
- Clinical Biochemistry
Background:
- Serum tumor markers are crucial for monitoring cancer treatment and relapse.
- Their diagnostic utility in identifying malignancy is well-established in clinical practice.
Observation:
- Two cases presented with significantly elevated serum tumor markers (alpha-fetoprotein and CA19-9) but no evidence of malignancy.
- One patient with autoimmune hepatitis showed markedly increased alpha-fetoprotein, which normalized with prednisone treatment.
- Another patient with biliary stone disease had very high CA19-9 levels, decreasing after biliary stenting.
Findings:
- Alpha-fetoprotein (aFP) levels can be significantly elevated in autoimmune hepatitis.
- CA19-9 levels can be markedly increased in benign biliary obstruction.
- These findings highlight that elevated tumor markers do not always signify cancer.
Implications:
- Relying solely on elevated serum tumor markers for cancer diagnosis can lead to misdiagnosis.
- Further investigation is necessary when tumor markers are elevated, especially in the absence of clinical suspicion for malignancy.
- These cases underscore the importance of considering benign etiologies for abnormal tumor marker levels.
